Clinicopathologic profile, immunophenotype, and genotype of CD274 (PD-L1)-positive colorectal carcinomas

Modern Pathology

Volumn 30, Issue 2, 2017, Pages 278-285

  Inaguma, Shingo ^a,b   Lasota, Jerzy ^a   Wang, Zengfeng ^a   Felisiak Golabek, Anna ^a   Ikeda, Hiroshi ^b   Miettinen, Markku ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; ALDH1A1 PROTEIN; B RAF KINASE; K RAS PROTEIN; PROGRAMMED DEATH 1 LIGAND 1; SALL4 PROTEIN; TRANSCRIPTION FACTOR CDX2; TUMOR MARKER; UNCLASSIFIED DRUG; ALCAM PROTEIN, HUMAN; ALDEHYDE DEHYDROGENASE; ALDH1A1 PROTEIN, HUMAN; BRAF PROTEIN, HUMAN; FETOPROTEIN; LEUKOCYTE ANTIGEN; NERVE CELL ADHESION MOLECULE; SALL4 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ADULT; AGED; ARTICLE; COLORECTAL CARCINOMA; CONTROLLED STUDY; FEMALE; GENOTYPE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; INTESTINE EPITHELIUM; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MISMATCH REPAIR; MUTATION; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; STEM CELL; TRANSVERSE COLON; VERY ELDERLY; COLORECTAL TUMOR; DNA MUTATIONAL ANALYSIS; GENETICS; MEDULLARY CARCINOMA; METABOLISM; PATHOLOGY;

AGED; AGED, 80 AND OVER; ALDEHYDE DEHYDROGENASE; ANTIGENS, CD; B7-H1 ANTIGEN; CARCINOMA, MEDULLARY; CDX2 TRANSCRIPTION FACTOR; CELL ADHESION MOLECULES, NEURONAL; COLORECTAL NEOPLASMS; DNA MISMATCH REPAIR; DNA MUTATIONAL ANALYSIS; FEMALE; FETAL PROTEINS; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MALE; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; TRANSCRIPTION FACTORS;

EID: 84994121565     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2016.185     Document Type: Article

References (34)

1. Nishimura H, Honjo T. PD-1: an inhibitory immunoreceptor involved in peripheral tolerance. Trends Immunol 2001; 22: 265-268
2. Nishimura H, Nose M, Hiai H, et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999; 11: 141-151
3. Dong H, Zhu G, Tamada K, et al. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999; 5: 1365-1369
4. Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000; 192: 1027-1034
5. Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001; 2: 261-268
6. Tseng SY, Otsuji M, Gorski K, et al. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J Exp Med 2001; 193: 839-846
7. Fanoni D, Tavecchio S, Recalcati S, et al. New monoclonal antibodies against B-cell antigens: possible new strategies for diagnosis of primary cutaneous B-cell lymphomas. Immunol Lett 2011; 134: 157-160
8. Terme M, Ullrich E, Aymeric L, et al. IL-18 induces PD-1-dependent immunosuppression in cancer. Cancer Res 2011; 71: 5393-5399
9. Fife BT, Bluestone JA. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev 2008; 224: 166-182
10. Gao Q, Wang XY, Qiu SJ, et al. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res 2009; 15: 971-979
11. Ohigashi Y, Sho M, Yamada Y, et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res 2005; 11: 2947-2953
12. Wu C, Zhu Y, Jiang J, et al. Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem 2006; 108: 19-24
13. Inaguma S, Wang Z, Lasota J, et al. Comprehensive immunohistochemical study of programmed cell death ligand 1 (PD-L1): analysis in 5536 cases revealed consistent expression in trophoblastic tumors. Am J Surg Pathol 2016; 40: 1133-1142
14. Masugi Y, Nishihara R, Yang J, et al. Tumour CD274 (PD-L1) expression and T cells in colorectal cancer. Gut 2016; doi: 10.1136/gutjnl-2016-311421
15. Rosenbaum MW, Bledsoe JR, Morales-Oyarvide V, et al. PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumorinfiltrating lymphocytes. Mod Pathol 2016; 29: 1104-1112
16. Droeser RA, Hirt C, Viehl CT, et al. Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. Eur J Cancer 2013; 49: 2233-2242
17. Lee LH, Cavalcanti MS, Segal NH, et al. Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma. Mod Pathol 2016; doi: 10.1038/modpathol.2016.139
18. JE IJ, Vermeulen L, Meijer GA, et al. Serrated neoplasiarole in colorectal carcinogenesis and clinical implications. Nat Rev Gastroenterol Hepatol 2015; 12: 401-409
19. Muto T, Bussey HJ, Morson BC. The evolution of cancer of the colon and rectum. Cancer 1975; 36: 2251-2270
20. Levin TG, Powell AE, Davies PS, et al. Characterization of the intestinal cancer stem cell marker CD166 in the human and mouse gastrointestinal tract. Gastroenterology 2010; 139: 2072-2082 e2075
21. Ginestier C, Hur MH, Charafe-Jauffret E, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007; 1: 555-567
22. Huang EH, Hynes MJ, Zhang T, et al. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res 2009; 69: 3382-3389
23. Cheng J, Deng R, Zhang P, et al. miR-219-5p plays a tumor suppressive role in colon cancer by targeting oncogene Sall4. Oncol Rep 2015; 34: 1923-1932
24. Dalerba P, Sahoo D, Paik S, et al. CDX2 as a prognostic biomarker in stage II and stage III colon cancer. N Engl J Med 2016; 374: 211-222
25. Miettinen M. A simple method for generating multitissue blocks without special equipment. Appl Immunohistochem Mol Morphol 2012; 20: 410-412
26. Lasota J, Kowalik A, Wasag B, et al. Detection of the BRAF V600E mutation in colon carcinoma: critical evaluation of the imunohistochemical approach. Am J Surg Pathol 2014; 38: 1235-1241
27. Kanda Y. Investigation of the freely available easy-Touse software EZR for medical statistics. Bone Marrow Transplant 2013; 48: 452-458
28. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkins lymphoma. N Engl J Med 2015; 372: 311-319
29. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-smallcell lung cancer. N Engl J Med 2015; 373: 1627-1639
30. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell nonsmall-cell lung cancer. N Engl J Med 2015; 373: 123-135
31. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015; 373: 1803-1813
32. Hwang WL, Yang MH, Tsai ML, et al. SNAIL regulates interleukin-8 expression, stem cell-like activity, and tumorigenicity of human colorectal carcinoma cells. Gastroenterology 2011; 141: 279-291
33. Marzec M, Zhang Q, Goradia A, et al. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci USA 2008; 105: 20852-20857
34. Parsa AT, Waldron JS, Panner A, et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 2007; 13: 84-88